Zacks Investment Research upgraded shares of Myovant Sciences (NYSE:MYOV) from a sell rating to a hold rating in a research report released on Wednesday morning.

According to Zacks, “Myovant Sciences Ltd. is a biopharmaceutical company. It focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders, including advanced prostate cancer. The company’s product candidate consists of relugolix which are in clinical trial, an oral once-daily small molecule that acts as a gonadotropin-releasing hormone receptor antagonist. Myovant Sciences Ltd. is based in Hamilton, Bermuda. “

Several other research firms have also recently issued reports on MYOV. JMP Securities reiterated an outperform rating and set a $25.00 price objective (up previously from $23.00) on shares of Myovant Sciences in a research report on Wednesday, October 4th. Robert W. Baird reiterated a buy rating and set a $20.00 price objective on shares of Myovant Sciences in a research report on Wednesday, October 4th. Finally, Cowen reiterated a buy rating on shares of Myovant Sciences in a research report on Tuesday, October 3rd. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $22.50.

Myovant Sciences (NYSE:MYOV) traded down $0.16 during trading on Wednesday, hitting $13.79. 48,582 shares of the stock traded hands, compared to its average volume of 26,233. The company has a market capitalization of $841.02 and a PE ratio of -9.78. Myovant Sciences has a 52-week low of $9.92 and a 52-week high of $18.85.

Myovant Sciences (NYSE:MYOV) last released its quarterly earnings data on Monday, November 13th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.12). sell-side analysts expect that Myovant Sciences will post -1.74 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the stock. Goldman Sachs Group Inc. purchased a new position in shares of Myovant Sciences in the second quarter valued at $174,000. Swiss National Bank purchased a new position in shares of Myovant Sciences in the second quarter valued at $294,000. OxFORD Asset Management LLP grew its holdings in shares of Myovant Sciences by 15.4% in the second quarter. OxFORD Asset Management LLP now owns 29,745 shares of the company’s stock valued at $348,000 after purchasing an additional 3,971 shares in the last quarter. Susquehanna International Group LLP purchased a new position in shares of Myovant Sciences in the second quarter valued at $648,000. Finally, Point72 Asset Management L.P. purchased a new position in shares of Myovant Sciences in the third quarter valued at $1,255,000. 79.21% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This piece was first reported by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/myovant-sciences-myov-rating-increased-to-hold-at-zacks-investment-research/1812868.html.

About Myovant Sciences

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

Get a free copy of the Zacks research report on Myovant Sciences (MYOV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.